StockNow
Log in
Global Markets

Novo Nordisk (NOVOB DC) wegovy pill 25mg showed greater mean weight loss vs. Orforglipron (LLY) 36mg in population-adjusted indirect treatment comparison

News detail

Population-adjusted indirect treatment comparison uses data from oasis 4 & attain-1 clinical trials. In separate patient preference study, 84% favoured wegovy pill 25mg-like treatment profile vs. Orforglipron-like profile. Orforglipron 36mg treatment had about 14 times higher discontinuation odds due to gastrointestinal adverse events vs wegovy pill 25mg.

2 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)